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Abstract  48 
Background: Helminth parasites have been reported to have beneficial immune modulatory 49 
effects in allergic and autoimmune conditions and detrimental consequences in tuberculosis 50 
and some viral infections. Their role in co-infection with respiratory viruses is not clear.  51 
Objective: Here, we investigated the effects of strictly enteric helminth infection with 52 
Heligmosomoides polygyrus on respiratory syncytial virus (RSV) infection in a mouse model.  53 
Methods: A murine helminth/ RSV co-infection model was developed. Mice were infected by 54 
oral gavage with 200 stage 3 H. polygyrus larvae. 10 days later, mice were infected with 55 
either RSV or UV-inactivated RSV (UV-RSV) intranasally.  56 
Results: H. polygyrus infected mice showed significantly less disease and pulmonary 57 
inflammation after RSV infection, associated with reduced viral load. Adaptive immune 58 
responses including Th2 responses were not essential since protection against RSV was 59 
maintained in RAG1-/- and IL-4Rα-/- mice. Importantly, H. polygyrus infection upregulated 60 
expression of type I IFNs and IFN stimulated genes (ISG) in both the duodenum and the 61 
lung, and its protective effects were lost in both IFNAR1-/- and germ-free mice, revealing 62 
essential roles for type I IFN signalling and microbiota in H. polygyrus induced protection 63 
against RSV. 64 
Conclusion: These data demonstrate that a strictly enteric helminth infection can have remote 65 
protective antiviral effects in the lung through induction of a microbiota-dependent type I 66 
IFN response.  67 
68 
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Key Messages 69 
• Strictly enteric helminth infection induces type I IFN production and ISG expression 70 
in both the duodenum and the lung. 71 
• Helminth-induced type I IFN signalling and the presence of the microbiota are critical 72 
for protection against RSV infection. 73 
 74 
Capsule Summary 75 
Strictly enteric helminth infection protects against RSV-infection through microbiota-76 
dependent induction of type I interferon in the lung, a novel mechanism which in the future 77 
may reveal new targets for the prevention and treatment of RSV infection. 78 
 79 
Key Words 80 
RSV; helminths; Heligmosomoides polygyrus; type I interferon; microbiome.  81 
 82 
Abbreviations used 83 
cDC: Conventional DC 84 
 ES: excretory secretory 85 
 HES: H. polygyrus ES 86 
 ISG: IFN stimulated gene 87 
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LRTI: lower respiratory tract infection 88 
PVM: pneumovirus of mice 89 
PRR: pathogen recognition receptor 90 
OAS: 2’ 5’ oligoadenylate synthetase 91 
RSV: respiratory syncytial virus  92 
93 
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INTRODUCTION 94 
Respiratory syncytial virus (RSV) is a major respiratory pathogen. It infects nearly all infants 95 
by the age of 2 years (1), but does not induce lasting immunity and leads to recurrent 96 
infections throughout life. It is estimated that worldwide, 33.4 million children under the age 97 
of 5 experience RSV lower respiratory tract infection (LRTI) annually and 10% of these 98 
require hospitalisation, resulting in up to 199,000 deaths (2-4). There is also major morbidity 99 
and mortality due to RSV in the elderly (5). Currently, there is no effective vaccine available 100 
for RSV, and treatment is limited to supportive care. Severe RSV LRTI is associated with 101 
and thought to be due to severe pulmonary inflammation.  102 
In addition, severe RSV infection during infancy has also been associated with increased risk 103 
for asthma development. There is substantial evidence indicating that children hospitalized 104 
with RSV-bronchiolitis, are more likely to experience recurrent wheezing episodes for a 105 
prolonged period of time after recovery from this illness (6-9).  106 
Helminths infect approximately 3 billion people worldwide. It has long been proposed that 107 
infection with helminths could suppress the development of immune-mediated disease, as in 108 
countries where their prevalence is high the prevalence of asthma, allergy, and autoimmune 109 
conditions has been found to be correspondingly low (10). Intestinal helminths in particular 110 
have been of major interest due to their ability to modulate host immune and inflammatory 111 
responses to foreign antigens (11-16) and several clinical trials have been carried out or are 112 
underway, assessing their utility as therapeutic agents in inflammatory bowel disease, 113 
multiple sclerosis and asthma (17).  114 
Helminth infections rarely occur in isolation and co-infections are very common with varying 115 
effects such as reduced pathogen control and increased disease, as reported for HIV infection 116 
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and tuberculosis (18-21). Recent experimental models in mice report reactivation of systemic 117 
latent γ-herpesvirus and reduced control of enteric norovirus replication (22, 23) indicating 118 
that in these systems, helminth infection suppresses anti-viral immunity resulting in increased 119 
viral replication. However, the impact of helminth infection on respiratory viruses is not well 120 
understood. Clinical data is lacking, but mouse models suggest reduced influenza-induced 121 
pathology in helminth co-infection (24, 25). 122 
Here, we investigated whether infection with the strictly enteric murine helminth 123 
Heligmosomoides polygyrus would change the course of disease and inflammation during 124 
RSV infection. This study demonstrates protective effects of helminth infection on RSV 125 
infection and reveals a novel mechanism of type I IFN induction by enteric helminth 126 
infection at a site distant from the gut.  127 
128 
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METHODS 129 
 130 
Animals 131 
BALB/c, C57BL/6, IL-4Rα-/-(79), RAG1-/-(80), IL-33R-/- (BALB/c background), IFNAR1-132 
/- (81) and Camp-/- (82) (bred to congenicity on a C57BL/6J Ola Hsd background) mice were 133 
bred in-house at the University of Edinburgh. Germ-free BALB/c mice were obtained from 134 
the Clean Mouse Facility (CMF), University of Bern, Bern, Switzerland, and were compared 135 
to SPF BALB/c mice from Charles River Breeding Laboratories (l'Arbresle Cedex, France). 136 
6-12 week old female mice were infected by oral gavage with 200 stage 3 H. polygyrus 137 
larvae. Ten days later, mice were intranasally infected with RSV or mock infected with UV-138 
inactivated RSV (UV-RSV) (standard coinfection protocol). 139 
 140 
Parasites, parasite products and virus stocks 141 
Parasites were maintained as previously described (83). Stage 3 H. polygyrus larvae were 142 
irradiated with 100, 200 or 300 Gy using a GSR-C1 irradiator at a rate of 6.2 Gy/min prior to 143 
administration by oral gavage. Axenic H. polygyrus larvae were produced as previously 144 
described (84). Plaque purified human RSV (Strain A2, ATCC, United States) was grown in 145 
Hep-2 cells as previously described (40).    146 
 147 
Whole body plethysmography 148 
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Baseline respiratory effort was assessed in individual mice, using whole body 149 
plethysmography (Buxco Europe, UK). Mice were placed into individual chambers, and 150 
baseline measurements were recorded for 5 minutes. Enhanced pause (Penh) values were 151 
recorded, averaged, and expressed as absolute values as previously described (85).  152 
 153 
RSV immunoplaque assay 154 
RSV titres were assessed as previously described (27), in lung homogenate by titration on 155 
HEp-2 cell monolayers in 96-well, flat-bottom plates. Twenty-four hours after infection, 156 
monolayers were washed, fixed with methanol, and incubated with peroxidase-conjugated 157 
goat anti-RSV antibody (Biogenesis, United Kingdom). Infected cells were detected using 3-158 
amino-9-ethylcarbazole and infectious units enumerated by light microscopy.  159 
 160 
Lung cell isolation and flow cytometry 161 
Right lung lobes were excised, cut into small pieces, incubated on a shaker with collagenase 162 
A (Sigma; 0.23 mg/ml PBS) at 37 °C for 45 minutes and sheared through a 19 gauge needle. 163 
After red blood cell lysis (Sigma), the single cell suspension was passed through a 40 μm cell 164 
strainer and stained using viability dye eFluor 780 (eBioscience, Hatfield, UK). The 165 
following anti-mouse antibodies were used to phenotype lung immune cells: PDCA-1 (EBIO-166 
927), Ly6G (RB6-C5), NKp46 (29A1.4), B220 (RA3-6B2) eFluor 450 conjugated 167 
(eBioscience), Ly6C (AL-21), CD8 (Ly-2) Fluorescein isothiocyanate (FITC) conjugated 168 
(BD Bioscience), CD11b (M1/70), CD4 (RM4-5) Phycoerythrin (PE) conjugated 169 
(eBioscience), CD45 (30-F11) eFluor605 Nanocrystal (NC605) conjugated (eBioscience), 170 
CD49B (DX5), CD19 (6D5) (Biolegend), F480 (Cl:A3-1) AlexaFluor 647 conjugated (AbD 171 
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Serotech) , MHCII (M5/114.15.2), CD3 (145-2C11) PercpCy5.5 conjugated (Biolegend), 172 
CD19 (EBIO1D3), CD3 (17A2) (eBioscience), Ly6G (1AB) AlexaFluor 700 conjugated (BD 173 
Bioscience) CD11c (N418) PE-Cy7 conjugated (eBioscience). Isotype control antibodies 174 
were used on pooled samples. Cells were gated as viable and CD45+ and subsequently 175 
phenotyped based on their markers as follows: Ly6G- CD19- CD3- CD49B+ NKp46+ NK 176 
cells, Ly6G- CD19- CD3- MHCII+ CD11B+ CD11C+ conventional dendritic cells, Ly6G- 177 
CD19- CD3+ CD4+ or CD8+ T cells, Ly6G- CD3- CD19+ CD19+ B220+ B cells. Samples 178 
were collected using LSR Fortessa II. Post-acquisition analysis performed using FlowJo 179 
version 7.6.5 software (treestar.inc, Oregon, USA).   180 
 181 
Real Time PCR 182 
Lung and duodenum was harvested and homogenised in 1 ml of TRIzol (Invitrogen) using a 183 
TissueLyser. Complementary DNA (cDNA) was made from the extracted RNA using the 184 
Qiagen QuantiTect Reverse Transcription Kit (Qiagen) following the manufacturer’s 185 
instructions. 1 μg RNA was used for the reverse transcription. Primers were diluted in TE 186 
buffer to a final concentration of 0.025 nM/μl and probes to 0.005 nM/μl. Custom primers 187 
and probes were purchased from Jena Bioscience or Applied Biosystems. PCR amplification 188 
was carried out in a 25 µl volume made up of custom 7 μl primer probe mix (300nM primers 189 
and 200nM probe), 12.5 μl TaqMan mastermix (Applied Biosystems); 1.75 μl H20; 1.25 μl 190 
18S (Applied Biosystems); 2.5 μl DNA template. 1.25 μl of pre-made primer probe mix was 191 
used in the following mixture: 12.5 μl mastermix; 5 μl H20; 1.25 μl 18S; 2.5 μl DNA 192 
template. IFN-β (Mm00439552_s1) and Camp (Mm00438285) primers and probes were 193 
bought premade from Life Technologies. Custom primers used are shown in Table I.  194 
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ELISA 195 
IFN-α and IFN-β was measured using an ELISA kit (PBL, Interferon Source) according to 196 
the manufacturer’s instructions. 197 
 198 
Statistical Analysis 199 
All data were analysed using Prism 6 (Graphpad, La Jolla, CA, USA). Analysis of 2 groups 200 
used an unpaired t-test. Analysis of 3 or more groups was either using One-way ANOVA 201 
with Tukey’s or Bonferroni’s post test or Two-way ANOVA with Bonferonni’s post test. 202 
Unless otherwise stated, the differences are non-significant. *** p <0.001; ** p  <0.01; * p 203 
<0.05. Outliers were tested for using Grubb’s test, and removed if determined to be an 204 
outlier. 205 
  206 
Study Approval  207 
All procedures were carried out with institutional ethical approval and under Home Office 208 
licences. Germ-free animal experiments were performed according to institutional guidelines 209 
and to Swiss Federal and Cantonal laws on animal protection. 210 
 211 
 212 
 213 
 214 
215 
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RESULTS 216 
H. polygyrus protects against RSV disease and inflammation and reduces viral load. 217 
Mice were infected with H. polygyrus, and 10 days later, when adult worms emerge into the 218 
lumen of the gut, mice were infected with RSV. H. polygyrus co-infection protected against 219 
RSV-induced weight loss (see Figure 1A) and reduced RSV-induced increases in enhanced 220 
pause, which are indicative of deterioration in baseline respiratory effort (see Figure 1B). 221 
RSV infection in the mouse model induces pulmonary inflammation with cellular infiltration, 222 
specifically of NK cells, CD8+ T cells and conventional DCs (cDC) (26, 27). In mice co-223 
infected with H. polygyrus, RSV-induced increases in NK cell, B cell (see Figure E1A and 224 
E1B in the Online Repository) and CD8+ T cell numbers were absent (see Figure 1C) while 225 
the increase in cDC numbers was significantly reduced (see Figure 1D). Early pro-226 
inflammatory cytokine production of IL-6 and TNF-α on day 2 was induced to a significantly 227 
lower level in H. polygyrus infected mice compared to those infected with RSV alone (see 228 
Figure E1C and E1D in the Online Repository). IFN-γ increased with RSV infection, but was 229 
not significantly suppressed in co-infected mice, indicating selective inhibition of a pathway 230 
independent of IFN-γ (see Figure E1E in the Online Repository).  231 
Given these changes in RSV-induced signs of disease, we asked whether H. polygyrus 232 
suppresses the immune response or directly alters magnitude of RSV infection. Lung RSV 233 
titres, assessed by plaque assay, were reduced following H. polygyrus infection, without 234 
changes in the kinetics of replication (see Figure 1E). In C57BL/6 mice ex-vivo plaque assays 235 
for RSV are unreliable due to low viral load (28), therefore we tested the effects of co-236 
infection in C57BL/6 mice by measuring expression of the RSV L gene in the lung by 237 
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RTPCR, as an indicator of viral load. L gene expression was, again, significantly reduced in 238 
H. polygyrus infected mice in this strain (see Figure E1F in the Online Repository). 239 
These findings demonstrate a potent inhibition of RSV-induced disease, early pro-240 
inflammatory cytokine production and recruitment of a broad range of immune cells to the 241 
lung in H. polygyrus co-infection presumably due to an early reduction in viral infection.  242 
Adaptive immune responses, including Th2 responses, are not required for H. 243 
polygyrus-induced protection against RSV infection.  244 
Type 2 immune responses are crucial during most helminth infections, aiding in wound 245 
healing and immunity to helminths (29-32). IL-4Rα-deficient mice cannot respond to IL-4 or 246 
IL-13 signals, and present strongly diminished type 2 immune responses (33). Consistent 247 
reductions in RSV titres were observed in H. polygyrus co-infected IL-4Rα-/- mice, similar to 248 
those seen in wild type BALB/c mice (see Figure 2A). We further assessed innate type 2 249 
immune responses, and found that following H. polygyrus infection, a non-significant trend 250 
for increased IL-13 producing ILC2s and IL-33 levels were observed in the lung tissue, 251 
compared to RSV and UV-RSV infected controls (see Figure E2A and E2B in the Online 252 
Repository). To investigate any protective role of IL-33 in response to RSV infection, we 253 
used IL-33R-/- mice. The RSV load was similar between IL-33R-/- and wild type control mice 254 
(see Figure E2C in the Online Repository), and was reduced to similar levels in both groups 255 
by H. polygyrus co-infection, indicating that there is no essential role for IL-33 in protection 256 
against RSV infection. 257 
To determine if any adaptive immune responses are required for H. polygyrus-mediated 258 
protection against RSV infection we used RAG1-deficient mice, which lack all T and B cells. 259 
Once again, RSV titres were significantly suppressed in both RAG1-/- mice and wild type 260 
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controls following co-infection with H. polygyrus (see Figure 2B). Together, these 261 
observations show that adaptive immune responses and IL-4Rα-dependent or IL-33R-262 
dependent type 2 cytokine responses are not required for the protective effect of H. polygyrus 263 
on RSV infection. 264 
H. polygyrus infection induces expression of type I IFN and IFN stimulated genes in 265 
both the duodenum and the lung. 266 
Type I IFNs are major players in the initial response to viral entry into the mucosa (34). Since 267 
adaptive and innate type 2 immune responses were not essential for the protection against 268 
RSV infection, we hypothesised that H. polygyrus enhances the mucosal innate IFN response 269 
conferring an antiviral state. 2’5’ oligoadenylate synthetase (Oas) and viperin are two of 270 
many IFN stimulated genes (ISG) which have been found to play a protective role in RSV 271 
infection and can be driven by type I IFN signalling (35-38). Gene expression of IFN-β, 272 
viperin, and OAS1a tended to increase in the duodenum from day 3 post-H. polygyrus 273 
infection (see Figure E3 in the Online Repository). Importantly, expression of these genes 274 
was also subsequently increased in the lung (see Figure 3A-C), despite the strictly enteric 275 
nature of H. polygyrus, and remained increased 1 hr after RSV infection (see Figure 3D-F), if 276 
this was preceded by H. polygyrus. By 6-12 hours after RSV infection, IFN-β transcripts 277 
reached the same levels in RSV mono- and co-infected mice (see Figure 3G and 3H). IFN-β 278 
protein levels measured by ELISA were below the detection limit at 1 hour after RSV 279 
infection and were found at similar levels between groups by 6 hours post-infection reflecting 280 
the RTPCR data. However, IFN-α protein was significantly increased at 6 hours after RSV 281 
infection (see Figure 3I). This data suggests that pre-existing upregulation of pulmonary type 282 
I IFN, viperin and OAS1a, prior to RSV infection, could underpin H. polygyrus-induced 283 
protection against RSV infection in the lung.  284 
285 
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H. polygyrus-induced protection against RSV infection requires type I IFN receptor 286 
signalling.  287 
Since ISG, including viperin and OAS1a, are expressed upon type I IFN receptor signalling, 288 
we used IFNAR1-deficient mice which fail to signal in response to IFN-α and IFN-β. In 289 
IFNAR1-/- mice the reduction of RSV load in H. polygyrus co-infection was lost, implying an 290 
essential role for this pathway in H. polygyrus induced protection against RSV infection (see 291 
Figure 4A). Furthermore, the ISG induction seen in wild-type mice is also lost in IFNAR-/- 292 
mice upon H. polygyrus infection (see Figure 4B and 4C).  293 
The cathelicidin CRAMP is upregulated during H. polygyrus infection but is not 294 
required for expression of type I IFN and ISGs. 295 
Cathelicidins are a family of small, cationic peptides with microbicidal and 296 
immunomodulatory properties (39). Humans and mice have only one cathelicidin, LL-37 and 297 
mCRAMP respectively, both of which have direct antiviral activity against RSV (40, 41). 298 
Cathelicidins have also been shown to promote type I IFN production by DCs (42, 43) and to 299 
enhance responses to viral RNA (44). Interestingly, expression of Camp (encoding 300 
mCRAMP) was also found to be upregulated in both the duodenum and the lung (see Figure 301 
E4A and 4B in the Online Repository) during H. polygyrus infection, with expression 302 
peaking prior to peak type I IFN and ISG expression, and remaining elevated 1 hour after 303 
RSV infection (see Figure E4C in the Online Repository). These data suggested that Camp 304 
expression might be upstream of these responses. Thus, H. polygyrus induced type I IFN and 305 
ISG expression was investigated in cathelicidin-deficient (Camp-/-) mice and was found to be 306 
intact (see Figure E4D-F in the Online Repository). This indicates that, while potentially 307 
contributing to the innate defence against RSV infection, mCRAMP is not the initiator of and 308 
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is not required for the protective antiviral immune response induced by H. polygyrus 309 
infection.  310 
H. polygyrus adult excretory secretory products are not responsible for the effects on 311 
RSV infection, while larval stages alone confer protection.  312 
Much interest has been building around the prospect of helminth excretory secretory (ES) 313 
products as potential therapeutics (45). H. polygyrus ES (HES), secreted by adult worms 314 
collected from the intestinal lumen, has been shown to have systemic effects in models of 315 
disease, and to mimic the effects of live infection (46). HES was administered in various 316 
regimes, by the intranasal and intraperitoneal routes, the day before RSV infection, for a 317 
week prior to infection, prior and post-infection and also by continuous HES treatment via an 318 
intraperitoneal osmotic mini-pump. None of these protocols resulted in significant reduction 319 
in viral titres when compared to RSV infected controls without HES treatment (see Figure E5 320 
in the Online Repository).  321 
The lack of protection afforded by adult worm products, together with the lack of 322 
requirement for an adaptive immune response caused us to question whether adult worms 323 
play any role in the interaction with RSV, or if larval stages of H. polygyrus and the damage 324 
associated with their initial invasion of submucosal tissue is key. Therefore, we irradiated 325 
stage 3 H. polygyrus larvae, as a non-lethal means of preventing their maturation to adulthood 326 
(47). The larvae are consequently able to penetrate the duodenal wall and enter into the 327 
submucosa, causing the initial trauma associated with infection, but do not re-emerge into the 328 
lumen as adults. Irradiated larvae also reduced RSV titres and induced IFN-β, Oas1a and 329 
viperin expression (see Figure 5A-D). No adults were found in the lumen in the 300Gy 330 
treated group, and numbers were severely reduced following 100Gy irradiation of larvae, but 331 
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granulomas were observed in all groups on the duodenal serosa (data not shown), confirming 332 
that the irradiated larvae were still able to invade the intestinal mucosal epithelium (48).  333 
The presence of the gut microbiota is essential for H. polygyrus induced protection 334 
against RSV infection. 335 
Larval stages of H. polygyrus protected against RSV infection, and this effect could be 336 
attributed to either the direct damage caused upon larval penetration of the submucosa, and/or 337 
the consequent translocation of intestinal bacteria into the mucosal tissues. To ascertain 338 
whether the microbiota play an important role in protection, we studied RSV infection in 339 
germ-free mice in the presence or absence of H. polygyrus infection.  340 
In contrast to fully-colonised SPF mice, in germ free mice RSV titres and RSV L gene 341 
expression were not supressed by H. polygyrus co-infection (see Figure 6A and 6B). 342 
Furthermore, the upregulation of type I IFN expression seen in the lung and duodenum of H. 343 
polygyrus infected SPF mice was absent in H. polygyrus infected germ free mice (see Figure 344 
6C and 6D). These data support a model in which the microbiota play a critical role in the 345 
induction of type I IFNs and ISGs during H. polygyrus infection, which in turn leads to 346 
functional antiviral protection in the lung.  347 
348 
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DISCUSSION 349 
Here we demonstrate that a strictly enteric helminth can have protective effects against RSV 350 
infection in the lung, through a mechanism mediated by microbiota-dependent type I IFN 351 
production. Firstly, we established that co-infection with H. polygyrus ameliorated RSV-352 
induced disease (manifesting as weight loss and increased respiratory effort) as well as 353 
reducing the production of pro-inflammatory cytokines and infiltration of immune cells (NK 354 
cells, cDCs, CD8+ T cells and B cells) into the lungs. Unexpectedly, this was associated with, 355 
and presumably a consequence of, a reduction in RSV load following H. polygyrus co-356 
infection. These protective effects were found to be independent of adaptive immune 357 
responses, including Th2 responses, as demonstrated in RAG-/- and IL-4Rα-/- mice 358 
respectively. In addition, these protective effects could not be replicated with HES treatment 359 
instead of live infection. Finally, enteric helminth infection upregulated antiviral type I IFN, 360 
ISG, and Camp gene expression in both the duodenum and the lung, and the protective 361 
effects of H. polygyrus on RSV infection were dependent on type I IFN receptor signalling 362 
and the presence of microbiota, as demonstrated in IFNAR1-/- and germ-free mice, which 363 
were not protected against RSV infection by H. polygyrus.  364 
The role of helminths in co-infections is not well understood (21). In particular, respiratory 365 
viral infection in the context of co-infection with helminths has not been investigated in 366 
epidemiological studies, nor in any great detail in animal models. H. polygyrus co-infection 367 
has previously been shown to reduce influenza virus titres and antibodies against the virus 368 
regardless of the lifecycle stage of helminth used (24). In addition, Trichinella spiralis was 369 
found to have protective effects against influenza infection that were dependent on the 370 
intestinal phase of infection, enhancing weight gain following influenza-induced weight loss 371 
and reducing cellular infiltration into the lung (25). These observations are similar to the 372 
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reduced weight loss observed in the H. polygyrus and RSV co-infection model reported here, 373 
and the reduced cellular infiltrate into the lung. However, the mechanisms involved in this 374 
protection were not elucidated in previous studies. More recently, chronic infection with 375 
Schistosoma mansoni provided significant protection against lethal influenza infection and 376 
infection with pneumovirus of mice (PVM) (49). This was found to be dependent upon the 377 
presence of eggs, which are known to cause significant damage to the gut wall. S. mansoni 378 
induced TNF-α dependent induction of Muc5ac and led to goblet cell hyperplasia in the lung, 379 
indicating increased epithelial barrier function. However, this was independent of type I IFN 380 
production, without any increase in type I IFN in the lung of S. mansoni infected mice over 381 
controls.  382 
Helminths induce a strong Th2 immune response, which is characterised by high levels of IL-383 
4, IL-5 and IL-13, infiltration of eosinophils, basophils and alternatively activated 384 
macrophages, as well as high production of IgE (30-32). In recently reported murine models, 385 
helminth induced type 2 immune responses and associated alternative macrophage activation 386 
aggravated γ-herpesvirus and norovirus infection (22, 23). However, our data show clearly 387 
that the Th2 response is not involved in protection against RSV which was maintained in IL-388 
4Rα-/- mice. In fact the helminth-induced adaptive immune response was all together 389 
dispensable for protection, indicating an important role for the innate antiviral immune 390 
response.  391 
Type I IFNs are an important part of the innate antiviral immune response that can be 392 
triggered through activation of pathogen recognition receptors (PRR) by viral components. 393 
They not only have direct antiviral activity, but they also have the ability to upregulate the 394 
expression of ISGs which have further antiviral potential, thus limiting viral infection and 395 
spread. Type I IFNs and ISGs are rapidly upregulated following RSV infection and decline 396 
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by 24 hours post infection (50, 51). The ISGs viperin and OAS, have previously been found 397 
to play a role in inhibiting RSV infection and have potent antiviral activity (36, 38). In 398 
murine models of RSV infection, prior administration of type I IFNs results in a decrease in 399 
replication and pathology upon RSV infection (52, 53). In addition, IFN-β treatment has also 400 
been shown to have antiviral effects against RSV, through the induction of proteases (54). 401 
Administration of recombinant type I IFN in humans has been limited thus far to IFN-α in the 402 
context of RSV infection (55-57) and nasal, but not intramuscular, administration prior to 403 
RSV challenge reduced signs and symptoms of upper respiratory tract infection (URTI) (56). 404 
Administration of recombinant ISGs has not been widely explored, however, RSV infection 405 
in chinchillas was reduced after transduction of the airways with vectors encoding viperin 406 
(36). However, there is very little evidence linking helminths and type I IFNs in the literature. 407 
Aksoy et al, found that double stranded structures found in S. mansoni egg RNA triggered 408 
TLR3 activation which in turn lead to the activation of the type I IFN response (58). In H. 409 
polygyrus infection, the type I IFN response has previously been reported to inhibit 410 
granuloma formation around larval parasites, but expression of the cytokines in direct 411 
response to infection was not measured (59).  412 
H. polygyrus infection induced upregulation of IFN-β transcript, and IFN-α protein levels in 413 
the lung at very early (< 6 hour post-infection) time points. This result, combined with the 414 
observation that the protective effect of H. polygyrus co-infection was lost in IFNAR 415 
deficient mice, indicates that upregulation of type I IFN expression by H. polygyrus is critical 416 
to its antiviral effects. While we were unable to detect IFN-β protein following H. polygyrus 417 
mono-infection or very early after RSV infection, the extensive gene expression data and in 418 
particular the induction of ISGs suggests that H. polygyrus induces type I IFN production, at 419 
levels too low to be detected by ELISA. We hypothesise that helminth infection and/or 420 
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associated bacterial exposure act as a weak signal for cells to produce low levels of type I 421 
IFN which through feedback via the IFNAR receptor, induce ISG transcription. This may 422 
prime cells to elicit rapid and strong type I IFN and ISG responses upon encounter of a strong 423 
stimulus, such as RSV (60). Such priming would benefit the host by enabling the fine balance 424 
between necessary rapid efficient anti-viral responses triggered by type I IFNs and 425 
detrimental inflammation and autoimmunity associated with chronic type I IFN responses 426 
(61). We observed a significant increase in IFN-α protein levels in the lungs of co-infected 427 
mice 6 hours post RSV infection. Previous reports indicate that IFN-β is effective in inducing 428 
IFN-α production (but not vice versa) (62), therefore we speculate that the early increase in 429 
IFN-β production could lead to the observed increase in IFN-α. Based on the recently 430 
described central role of alveolar macrophages in the production of type I IFN during RSV 431 
infection (63), we speculate that these cell are also the likely source of helminth induced type 432 
I IFN in the lung.  433 
Irradiation of stage 3 H. polygyrus larvae has been previously shown to inhibit their 434 
maturation, but allows larval migration into the intestinal submucosa, after which point the 435 
larvae do not develop further into adults (47). By taking this approach, we demonstrated that 436 
larval stages are sufficient to induce IFN-β and ISG gene expression and to confer protection 437 
against RSV infection. Further investigation in germ free mice revealed a requirement for 438 
microbiota in helminth-induced IFN-β upregulation and resistance to viral replication. It is 439 
therefore plausible to speculate that the damage caused by initial penetration of larvae into 440 
the submucosa may result in bacterial translocation from the gut and activation or priming of 441 
the innate immune response. Indeed, upregulation of type I IFNs at epithelial barrier surfaces 442 
can reduce bacterial translocation by upregulating tight junctions (64). Thus bacterial 443 
translocation in the intestine during H. polygyrus infection may induce upregulation of type I 444 
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IFNs systemically to limit such translocation. In addition, commensal, but not pathogenic, 445 
bacteria have been shown to induce type I IFN production and can also provide protection 446 
against influenza infection (65-67). Furthermore, helminth infection has been shown to alter 447 
the microbiome in the intestine of both humans and mice. A study conducted in Malaysia 448 
indicated that helminth infected people had a greater bacterial number and richer diversity, 449 
with increases in specific bacterial taxa, than uninfected controls (68). Likewise in mice, 450 
parasites including Trichuris muris and H. polygyrus have been found to alter the balance of 451 
commensals in the intestine (69, 70). A specific increase in Lactobacillus species has been 452 
noted during H. polygyrus infection (70). Interestingly, the administration of Lactobacillus 453 
species prior to RSV infection, either by intranasal or oral routes, can increase antiviral 454 
immunity, including an increase in IFN-β in the bronchoalveolar lavage and therefore 455 
resistance to RSV infection (71, 72). 456 
Viral LRTI with RSV and rhinoviruses in the first years of life has been linked to the 457 
development of asthma (73-75), which helminth infections have been shown to protect 458 
against in mouse model systems (76, 77). In parallel, intestinal helminth infections in humans 459 
have been reported to increase bacterial translocation (78). Thus, we speculate that helminth 460 
infection may protect against severe respiratory viral infections in early life, and that this 461 
effect in turn may contribute to a reduced potential for asthma development.   462 
In conclusion, we show that intestinal helminth infection can be beneficial in respiratory viral 463 
infection. Based on our findings we hypothesise that helminth infection in the gut triggers 464 
type I IFN production through bacterial interactions, which leads to systemic type I IFN 465 
induction thus raising preparedness of remote sites such as the lung to mount an effective 466 
innate response against incoming unrelated viral pathogens. In addition to these findings, 467 
further work will be required to elucidate the exact mechanisms of H. polygyrus induced 468 
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antiviral effects, and thus inform potential translation towards new helminth-based 469 
approaches to prevention and treatment of respiratory viral disease.  470 
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Table-I: Primers used for Real-time PCR  682 
  683 
684 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Probe (FAM-TAMRA 5’-3’) 
OAS-1a TCCTGGGTCATGTT
AATACTTCCA 
GAGAGGGCTGTGG
TGGAGAA 
CAAGCCTGATCCCAGAA
TCTATGCC 
Viperin CGAAGACATGAAT
GAACACATCAA 
AATTAGGAGGCAC
TGGAAAACCT 
CCAGCGCACAGGGCTC
AGGG 
RSV-L GAACTCAGTGTAG
GTAGAATGTTTGC
A 
TTTCAGCTATCATT
TTCTCTGCCAAT 
TTTGAACCTGTCTGAAC
ATTCCCGGTT 
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Figure legends 685 
Figure 1. H. polygyrus infection attenuates RSV disease and inflammation and reduces 686 
RSV viral load.  687 
The standard co-infection protocol was used as follows: female BALB/c mice were given 200 688 
H. polygyrus L3 larvae by oral gavage at day -10 or left naive. At day 0, 6x10
5 
PFU (A, B) or 689 
4x10
5
 PFU (C, D, E) RSV or UV-inactivated RSV was administered intranasally, (A) Mice 690 
were weighed daily and percentage of original weight is shown; (B) Enhanced pause (penH) 691 
was assessed by whole body plethysmography (WBP); (C, D) Samples were taken at the 692 
indicated time points after RSV infection for flow cytometric analysis. Numbers of CD3
+
 693 
CD8
+
 T cells (C) and of MHCII
+
CD11b
+
CD11c
+ 
conventional dendritic cells (D) per right 694 
lung lobe are shown; (E) Lungs were harvested on days 3, 4 and 6 post RSV infection and 695 
plaque assays performed. All data are depicted as mean ± SEM. Data in A & B pooled from 2 696 
independent experiments, total n=8 per group, in C, D & E from 2 independent experiments, 697 
total n=6 per group per time point. Statistical significance of differences between RSV 698 
infected groups was determined by two-way ANOVA with Bonferroni’s post hoc 699 
test.*P<0.05, **P<0.01, ***P<0.001. 700 
 701 
Figure 2. Adaptive immune responses, including Th2 responses, are not required for the 702 
H. polygyrus-mediated attenuation of RSV viral titres.  703 
The standard co-infection protocol was followed (A) in BALB/c IL-4Rα deficient mice and 704 
(B) in BALB/c RAG1 deficient mice. Lungs were harvested on day 4 of RSV infection and 705 
plaque assays performed to determine RSV titres. All data are depicted as mean ± SEM. Data 706 
in A are pooled from 2 individual experiments, total n=4-8 per group. Data in B are 707 
representative of 2 independent experiments, n=3-4 per group. Statistical significance 708 
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between groups was determined by one-way ANOVA with Tukey’s post hoc test. *P<0.05, 709 
**P<0.01.  710 
 711 
Figure 3. H. polygyrus induces type I IFN and associated gene expression in the lung.  712 
BALB/c (A-C) were given 200 L3 H. polygyrus larvae or left naïve. At indicated time-points 713 
post-H. polygyrus infection half of the large left lung lobe was placed in Trizol and RTPCR 714 
was performed for expression levels of (A) IFN-β, (B) OAS1a or (C) viperin in lung 715 
comparing H. polygyrus infected to naïve mice. The standard co-infection protocol was 716 
followed in BALB/c mice (D-I). 1 hour after RSV infection half of the large left lung lobe 717 
was placed in Trizol and RTPCR was performed for expression levels of (D) IFN-β (E) 718 
OAS1a (F) viperin. (G-I) 1 (data from Fig. 3A), 6 and 12 hours post-RSV infection half of 719 
the large left lung lobe was placed in (G) Trizol and RTPCR was performed for expression 720 
levels of IFN-β; (H&I) was homogenized and (H) IFN-β and (I) IFN-α protein levels were 721 
analysed by ELISA. (A-G) results were normalised to 18S expression and represented as fold 722 
change in expression over naïve controls (A-C), UV-RSV controls (D-G). Data are depicted 723 
as mean ± SEM. Data are pooled in A-I from 2 independent experiments, total n=6-8 per 724 
group and in I from 2 individual experiments, total n=10 per group. Statistical significance of 725 
differences between groups was determined, A-C by one-way ANOVA with Bonferroni’s 726 
post hoc test and in D-I by two-way ANOVA with Bonferroni’s post hoc test. *P<0.05, 727 
**P<0.01, ***P<0.001, NS = non-significant. 728 
 729 
Figure 4. Type I IFN signalling is essential for H. polygyrus-induced protection against 730 
RSV.  731 
(A) The standard co-infection protocol was followed in C57BL/6 or IFNAR1 deficient mice 732 
or were given 200 L3 H. polygyrus larvae or left naïve. 3 days post-RSV infection half of the 733 
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large left lung lobe was placed in Trizol and RTPCR was performed for expression of RSV L 734 
gene. (B&C) 10 post-H. polygyrus infection half of the large left lung lobe was placed in 735 
Trizol and RTPCR was performed for expression levels of (B) OAS1a or (C) viperin in lung 736 
comparing H. polygyrus infected to naïve mice. All results were normalised to 18S 737 
expression and represented as fold change in expression over naïve/RSV controls. Data are 738 
depicted as mean ± SEM. Data are pooled from 2 independent experiments, total n=6-10 per 739 
group. Statistical significance of differences between groups was determined by two-way 740 
ANOVA with Bonferroni’s post hoc test. *P<0.05, **P<0.01, ***P<0.001, NS = non-741 
significant. 742 
 743 
Figure 5. H. polygyrus larval stages are sufficient to protect against RSV infection.  744 
200 L3 H. polygyrus larvae were irradiated at 300 Gy and compared to non-irradiated larvae 745 
in (A) standard co-infection protocol; or (B-D) to naïve controls following H. polygyrus 746 
infection alone. (A) Lungs were harvested on day 4 of RSV infection and plaque assays 747 
performed. (B-D) On day 10 of H. polygyrus infection the right lung lobes were removed and 748 
placed in Trizol for RTPCR for IFN-β, OAS1a and viperin. All results were normalised to 749 
18S expression and represented as fold change in expression over controls. All data are 750 
depicted as mean ± SEM. A-D is representative of two individual experiments, total n=3-4 751 
per group. Statistical significance of differences between groups was determined in (A) by 752 
one-way ANOVA with Tukey’s post hoc test and (B) by unpaired t-test. *P<0.05, **P<0.01, 753 
***P<0.001, NS= non-significant. 754 
 755 
Figure 6. Microbiota are required to protect against RSV infection.  756 
The standard co-infection protocol was followed in BALB/c germ-free and SPF mice, using 757 
400L3 germ free H. polygyrus larvae and 3x107 sterile RSV in 100µl. On day 4 after RSV 758 
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infection, (A) the left lung lobe was removed and plaque assays performed; (B) the right lung 759 
lobes were removed and placed in Trizol for RTPCR for RSV L gene or (C) IFN-β 760 
expression; (D) the first centimetre of the duodenum was removed and placed in Trizol and 761 
RTPCR was performed for expression of IFN-β. Results in B-D are normalised to 18S and 762 
represented as fold change in expression over SPF RSV infected controls. All data are 763 
depicted as mean ± SEM. All data are representative of two individual experiments, total 764 
n=3-4 per group. Statistical significance of differences between groups was determined by 765 
unpaired t-test. *P<0.05, **P<0.01, ***P<0.001, NS= non-significant. 766 
 767 
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 845 
METHODS 846 
Cytometric Bead Array 847 
Half of the left lung lobe was homogenised using a TissueLyser (Qiagen) in 0.5ml of 1x cell 848 
lysis buffer (Cell Signalling, Danvers, MA, USA) containing 1µg PMSF (Sigma). Cytokines 849 
present in the lung homogenate were detected through the use of a Cytokine Bead Array flex 850 
set (BD Biosciences), following the manufacturer’s protocol was followed. Samples were 851 
collected on the FACS Array (BD) and analyzed using Flowjo software (version 7.6.5). 852 
ELISA 853 
IL-33 was measured using the R&D Systems ELISA kit according to the manufacturer’s 854 
instructions. 855 
Osmotic Minipump Surgery 856 
Minipumps (Alzet, Cupertino, CA) were filled with the appropriate volume and concentration 857 
of HES prior to implantation, and primed in saline at 37°C overnight. Mice were placed 858 
under general anaesthesia using inhalable isoflurane and were given 0.1mg/kg subcutaneous 859 
buprenorphine. The peritoneal cavity area was shaved and the area was swabbed with alcohol 860 
to provide a sterile environment. A midline incision was made just below the ribcage, about 861 
1cm in length. The musculoperitoneal layer was lifted using forceps to avoid internal 862 
damage, and an incision was made in the peritoneal wall beneath. The primed minipump was 863 
then inserted into the cavity, with the delivery port entering first, and the wound was then 864 
closed using interrupted sutures. Mice were monitored upon recovery from anaesthetic, and 865 
were given a further 0.1mg/kg subcutaneous buprenorphine post-op 866 
867 
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 868 
Figure legends 869 
Figure E1: H. polygyrus infection attenuates RSV inflammation and reduces viral load. 870 
The standard co-infection protocol was followed. Samples were taken at the indicated time 871 
points after RSV infection for flow cytometric analysis. (A) Total number of 872 
CD49B+NKP46+ NK cells per right lung lobe; (B) Total number MHCII+CD19+B220+ B 873 
cells per right lung lobe;  (C, D) Half of the left lung lobe was homogenized and cytokine 874 
levels were analysed by Cytometric Bead Array (CBA) levels of (C) IL-6 and (D) TNF-α (E) 875 
IFN-γ levels were determined. (F) The standard co-infection protocol was followed in female 876 
C57BL/6 mice. 3 days post-RSV infection half of the large left lung lobe was placed in Trizol 877 
and RT-PCR was performed for expression of the RSV L gene. All data are depicted as mean 878 
± SEM and are pooled from 2 independent experiments, total n=6 per group per time point. 879 
Statistical significance of differences between RSV infected groups were determined, in A-E 880 
by two-way ANOVA with Bonferroni’s post hoc test and in F by unpaired t-test.  *P<0.05, 881 
***P<0.001. 882 
 883 
Figure E2: IL-33 is not essential for protection against RSV. 884 
The standard co-infection protocol was followed in (A & B) BALB/c or in (C) BALB/c IL-885 
33R-/- mice. Samples were taken 1 hour after RSV infection (A) for flow cytometric analysis 886 
of numbers of ICOS+ IL-13+ ILCs per right lung lobe; (B) half of the left lung lobe was 887 
homogenized and cytokine levels were analysed by ELISA; (C) The standard co-infection 888 
protocol was followed in BALB/c IL-33R-/- mice. Lungs were harvested on day 4 of RSV 889 
infection and plaque assays performed to determine titres. All data are depicted as mean ± 890 
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SEM. Data are pooled from 2 independent experiments, total n=6-8 per group. Statistical 891 
significance of differences between groups was determined by two-way ANOVA with 892 
Bonferroni’s post hoc test. *P<0.05, **P<0.01, ***P<0.001. 893 
 894 
Figure E3: H. polygyrus induces type I IFN and associated gene expression in the 895 
intestine.  896 
BALB/c mice were given 200 L3 H. polygyrus larvae or left naïve. The 1st cm of the 897 
duodenum was placed in Trizol and RT-PCR was performed for expression levels of IFN-β, 898 
OAS1a, Viperin (A-C) comparing H. polygyrus infected to naïve mice. Results were 899 
normalised to 18S expression and represented as fold change in expression over naïve 900 
controls. Data are depicted as mean ± SEM. Data are pooled from 2 independent 901 
experiments, total n=6-8 per group. Statistical significance of differences between groups was 902 
determined by one-way ANOVA with Bonferroni’s post hoc test. **P<0.01 903 
 904 
Figure E4: Camp does not drive type I IFN and ISG expression in the lung.  905 
BALB/c mice were given 200 L3 H. polygyrus larvae or left naïve. (A) The 1st cm of the 906 
duodenum and (B) half of the large left lung lobe was placed in Trizol and RT-PCR was 907 
performed for expression levels of Camp comparing H. polygyrus infected to naïve mice. (C) 908 
The standard co-infection protocol was followed in BALB/c mice and 1 hour after RSV 909 
infection half of the large left lung lobe was placed in Trizol and RT-PCR was performed for 910 
expression levels of Camp. (D-F) C57BL/6 or Camp-/- mice were given 200L3 H. polygyrus 911 
by oral gavage or left naïve. Half of the large left lung lobe was placed in Trizol and RT-PCR 912 
was performed for expression levels of (D) IFN-β, (E) OAS1a, and (F) Viperin. All results 913 
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were normalised to 18S expression and represented as fold change in expression over naïve 914 
controls (A & B), UV-RSV controls (C), or C57BL/6 naive controls (D-F). Data are depicted 915 
as mean ± SEM. Data are pooled from 2 independent experiments, total n=6-8 per group. 916 
Statistical significance of differences between groups was determined in A & B by one-way 917 
ANOVA with Bonferonni’s post-hoc test and in C-F by two-way ANOVA with Bonferroni’s 918 
post hoc test. *P<0.05, **P<0.01, ***P<0.001. 919 
 920 
Figure E5: RSV titres are not inhibited by HES administration.  921 
5μg HES was given to mice (A) intranasally on day -1 & 0, (B) intranasally on day -7, -4, -1 922 
& 0, (C) intraperitoneally on day -7, -4, & -1. Osmotic minipumps containing HES were 923 
surgically implanted on (D) day -7, (E) day -10, releasing 0.25 µl HES per hour for 10 or 14 924 
days respectively. On day 0 4x105 PFU RSV was administered intranasally. Lungs were 925 
harvested on day 4 of RSV infection and plaque assays performed. All data are depicted as 926 
mean ± SEM, total n=4 per group. Statistical significance of differences between groups was 927 
determined by unpaired t-test. NS= non-significant. 928 
 929 
 930 
